Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
2023 Terapias Dirigidas en el Foro de Pacientes con Cáncer de Pulmón
El vídeo completo sin editar está disponible On Demand
|
AGENDA del Foro de Terapias Dirigidas en Pacientes con Cáncer de Pulmón 2023 Spanish 2023 Targeted Therapies in Lung Cancer Patient Forum AGENDAPresidente del evento / Event Chair Luis Raez, MD
|
Available DownloadableDocuments
|
|
|
9:00 AM
|
Bienvendia y Palabras de Apertura / Welcome and Opening Remarks Event Chair: Dr. Luis Raez
|
|
|
9:10 AM
9:55 AM
10:25 AM
10:55 AM
|
Discusion del Panel: Presentaciones de Casos con Mutaciones EGFR y Resistencia Panel Discussion: Presentation of Cases with EGFR Mutation and Resistance Cases/moderator: Dr. Fernando Diaz, Panel: Alberto Chiappori, Luis Corrales, Estelamari Rodriguez
Desafíos en el Diagnóstico Molecular y el Papel Que Juegan las Biopsias Líquidas Challenges in Molecular Diagnostics and the Role of Liquid Biopsies Dr. Luis Raez
Terapias Dirigidas para Tumores KRAS Targeted Therapies for KRAS+ Tumors Dr. Luis Corrales
Terapias Dirigidas Para NSCLC Temprana Targeted Therapies for Early NSCLC Dr. Estelamari Rodriguez |
Download Slides: Discusion del Panel: Presentaciones de Casos con Mutaciones EGFR y Resistencia
Download Slides: Desafíos en el Diagnóstico Molecular y el Papel Que Juegan las Biopsias Líquidas
Download Slides: Terapias Dirigidas para Tumores KRAS
Download Slides: Terapias Dirigidas Para NSCLC Temprana
|
|
11:25 AM
|
Panel y Q&A Panel and Q&A Dr. Luis Raez (moderator), Diaz, Corrales, Chiappori, Rodriguez |
|
| 11:45 AM |
Mensaje de Agradecimiento y Despedida / Thank you and Closing Event Chair: Dr. Luis Raez |
|
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…